Max, formerly known as HBO Max, officially has a new logo on Sunday night, March 30. The new logo for Warner Bros. Discovery's steaming platform was unveiled on Sunday evening. The new logo gives ...

Much of the damage was done in December when the stock tanked after CagriSema, Novo’s experimental anti-obesity drug, achieved a 22.7 per cent weight loss in a clinical trial, slightly below its ...

Copenhagen, DENMARK — Novo Nordisk defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss ...

The company is developing CagriSema as a weight management medicine. In December, Novo Nordisk reported that CagriSema helped patients lose, on average, 22.7% of their body weight in a phase 3 study.

CagriSema has had parallel studies completed, setting it up to be available for both diabetes and obesity treatment. What's more, the Danish giant has just announced a US$2-billion deal with ...

That tipped it past Novo Nordisk, whose shares have declined 18% this year due to disappointing trials of its next-generation weight-loss shot CagriSema.

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...